Why it is different
Semaglutide activates GLP-1. Tirzepatide activates GIP and GLP-1. Retatrutide adds glucagon-receptor activity, creating a triple agonist. “GLP-3” is a media nickname, not a scientific drug class.
Evidence over hype
The full story on retatrutide.
The results are remarkable. The drug is still investigational. Here is what the peer-reviewed studies, Phase 3 announcements and safety data actually say—without selling you anything.
28.3%
Average weight reduction at 80 weeks with 12 mg in TRIUMPH-1’s efficacy estimate. Company-reported Phase 3 topline result; peer-reviewed publication pending.
Primary sources firstPeer-reviewed journals and trial registries
Evidence labeledPublished data separated from company topline results
Bottom line: Retatrutide remains investigational. Anonymous products sold through “research peptide” websites, social-media sellers or unverified clinics have not been shown equivalent to controlled trial supplies and may be mislabeled, contaminated or incorrectly dosed. A lawfully compounded patient-specific medication from a licensed pharmacy is a separate category and should not be confused with a bulk research vial.
The short version
What is retatrutide?
Retatrutide (LY3437943) is an experimental once-weekly injection developed by Eli Lilly. One molecule activates three hormone receptors involved in appetite, glucose regulation and energy balance: GIP, GLP-1 and glucagon.
Why researchers are interested
Trials have reported substantial weight reduction, improved A1C and reductions in liver fat. Phase 3 programs also study knee osteoarthritis pain, sleep apnea, cardiovascular and kidney outcomes.
What remains unknown
Long-term real-world safety, durability after discontinuation, final labeling, price, coverage and comparative effectiveness remain unresolved. The head-to-head tirzepatide trial is ongoing.
One molecule, three targets
A coordinated metabolic signal
The exact contribution of each receptor is still being studied. The overall drug effect cannot be reduced to any one pathway.
GIP receptor
Supports glucose-dependent insulin signaling and may work with GLP-1 activity to improve metabolic control.
GLP-1 receptor
Supports satiety, glucose-dependent insulin release and slower gastric emptying, especially early in treatment.
Glucagon receptor
May increase energy expenditure and influence liver metabolism while the other receptor actions help control glucose.
Results at a glance
The numbers people are talking about
These figures come from different trials, populations, durations and statistical approaches. They should not be used as a direct comparison with other medications.
24.2%Mean weight reduction at 48 weeks with 12 mg in the peer-reviewed Phase 2 obesity trial; placebo: 2.1%.
28.3%Mean weight reduction at 80 weeks with 12 mg in company-reported TRIUMPH-1 efficacy results; placebo: 2.2%.
−1.94Percentage-point A1C change at 40 weeks with 12 mg in peer-reviewed Phase 3 diabetes results; placebo: −0.81.
82.4%Relative liver-fat reduction at 24 weeks with 12 mg in a 98-person Phase 2a MASLD substudy; placebo: +0.3%.
Sources: New England Journal of Medicine (2023), Nature Medicine (2024), The Lancet (2026), and Lilly TRIUMPH-1 topline release (2026). See the resource library.
Results need context
Promising is not the same as proven for everyone
High-dose results attract the headlines, but the same trials show dose-related tradeoffs. In TRIUMPH-1, nausea, diarrhea, constipation and vomiting were common. Abnormal skin sensations called dysesthesia occurred in 12.5% of the 12 mg group versus 0.9% with placebo, and 11.3% stopped treatment because of adverse events versus 4.9% with placebo.
Phase 3 cardiovascular event counts were too small and confidence intervals too wide to establish cardiovascular benefit or harm. There is not yet an approved prescribing label defining who should take retatrutide, contraindications, warnings or a public dosing schedule.
Read the balanced safety review
Start with the strongest evidence
Read the studies before the social-media claims.
The curated library includes the major peer-reviewed trials, the active head-to-head study, official development updates, independent reporting and clinician-led video explanations.
FREE TEN PAGE RETATRUTIDE REPORT
The latest peer-reviewed evidence on efficacy, safety, and where retatrutide clinical trials stand today. No cost, no obligation.